Suppr超能文献

不完善的疫苗诱导免疫和百日咳向婴儿的传播。

Imperfect vaccine-induced immunity and whooping cough transmission to infants.

机构信息

Department of Biology, 501 ASI Bldg, Penn State University, University Park, PA 16802, USA.

出版信息

Vaccine. 2010 Dec 10;29(1):11-6. doi: 10.1016/j.vaccine.2010.10.029. Epub 2010 Oct 27.

Abstract

Whooping cough, caused by B. pertussis and B. parapertussis, has increased in incidence throughout much of the developed world since the 1980s despite high vaccine coverage, causing an increased risk of infection in infants who have substantial disease-induced mortality. Duration of immunity and epidemically significant routes of transmission across age groups remain unclear and deserve further investigation to inform vaccination strategies to better control pertussis burden. The authors analyze age- and species-specific whooping cough tests and vaccine histories in Massachusetts from 1990 to 2008. On average, the disease-free duration is 10.5 years. However, it has been decreasing over time, possibly due to a rising force of infection through increased circulation. Despite the importance of teenage cases during epidemics, wavelet analyses suggest that they are not the most important source of transmission to infants. In addition, the data indicate that the B. pertussis vaccine is not protective against disease induced by B. parapertussis.

摘要

百日咳由 B. pertussis 和 B. parapertussis 引起,尽管疫苗接种率很高,但自 20 世纪 80 年代以来,在许多发达国家的发病率都有所上升,这导致了婴儿感染的风险增加,而婴儿因该病的死亡率很高。免疫持续时间和在各年龄组中具有流行病学意义的传播途径仍不清楚,值得进一步研究,以制定更好的疫苗接种策略来控制百日咳负担。作者分析了马萨诸塞州 1990 年至 2008 年期间的年龄和物种特异性百日咳检测和疫苗接种史。平均而言,无病持续时间为 10.5 年。然而,它随着时间的推移而减少,可能是由于感染率上升导致循环增加。尽管青少年病例在流行期间很重要,但小波分析表明,他们并不是向婴儿传播的最重要来源。此外,数据表明,百日咳疫苗不能预防由 B. parapertussis 引起的疾病。

相似文献

1
Imperfect vaccine-induced immunity and whooping cough transmission to infants.
Vaccine. 2010 Dec 10;29(1):11-6. doi: 10.1016/j.vaccine.2010.10.029. Epub 2010 Oct 27.
2
Bordetella pertussis, B. parapertussis, vaccines and cycles of whooping cough.
Pathog Dis. 2015 Oct;73(7). doi: 10.1093/femspd/ftv055. Epub 2015 Aug 4.
3
Do Pertussis Vaccines Protect Against Bordetella parapertussis?
Clin Infect Dis. 2017 Jun 15;64(12):1795-1797. doi: 10.1093/cid/cix221.
4
Surveillance of pertussis: methods and implementation.
Expert Rev Anti Infect Ther. 2016 Jul;14(7):657-67. doi: 10.1080/14787210.2016.1190272. Epub 2016 May 31.
5
Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
Vaccine. 2010 Jun 17;28(27):4362-8. doi: 10.1016/j.vaccine.2010.04.053. Epub 2010 May 15.
6
Re-emergence of pertussis: what are the solutions?
Expert Rev Vaccines. 2012 Nov;11(11):1331-46. doi: 10.1586/erv.12.118.
7
Development of improved pertussis vaccine.
Hum Vaccin Immunother. 2014;10(8):2450-3. doi: 10.4161/hv.29253.
8
Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.
Vaccine. 2012 Jan 11;30(3):544-51. doi: 10.1016/j.vaccine.2011.11.065. Epub 2011 Nov 26.
9
Bordetella pertussis: why is it still circulating?
J Infect. 2014 Jan;68 Suppl 1:S119-24. doi: 10.1016/j.jinf.2013.09.022. Epub 2013 Oct 5.

引用本文的文献

1
Dissecting recurrent waves of pertussis across the boroughs of London.
PLoS Comput Biol. 2022 Apr 14;18(4):e1009898. doi: 10.1371/journal.pcbi.1009898. eCollection 2022 Apr.
2
Experts' Opinion for Improving Pertussis Vaccination Rates in Adolescents and Adults: A Call to Action.
Int J Environ Res Public Health. 2022 Apr 6;19(7):4412. doi: 10.3390/ijerph19074412.
4
Immunomodulation as a Novel Strategy for Prevention and Treatment of spp. Infections.
Front Immunol. 2019 Dec 13;10:2869. doi: 10.3389/fimmu.2019.02869. eCollection 2019.
5
The impact of past vaccination coverage and immunity on pertussis resurgence.
Sci Transl Med. 2018 Mar 28;10(434). doi: 10.1126/scitranslmed.aaj1748.
6
Strategic Approaches Towards Pertussis Control in Oman.
Oman Med J. 2018 Jan;33(1):29-36. doi: 10.5001/omj.2018.06.
7
Bordetella parapertussis outbreak in Southeastern Minnesota and the United States, 2014.
Medicine (Baltimore). 2017 May;96(20):e6730. doi: 10.1097/MD.0000000000006730.
9
Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine.
Hum Vaccin Immunother. 2016 Nov;12(11):2742-2748. doi: 10.1080/21645515.2016.1201622. Epub 2016 Jul 7.
10
Estimated incidence of pertussis in people aged <50 years in the United States.
Hum Vaccin Immunother. 2016 Oct 2;12(10):2536-2545. doi: 10.1080/21645515.2016.1186313. Epub 2016 May 31.

本文引用的文献

1
Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis.
Proc Biol Sci. 2010 Jul 7;277(1690):2017-25. doi: 10.1098/rspb.2010.0010. Epub 2010 Mar 3.
2
Bordetella pertussis strains with increased toxin production associated with pertussis resurgence.
Emerg Infect Dis. 2009 Aug;15(8):1206-13. doi: 10.3201/eid1508.081511.
3
Seasonal patterns in time series of pertussis.
Epidemiol Infect. 2009 Oct;137(10):1388-95. doi: 10.1017/S0950268809002489. Epub 2009 Mar 30.
4
The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity.
Infect Immun. 2007 Oct;75(10):4972-9. doi: 10.1128/IAI.00763-07. Epub 2007 Aug 13.
5
The control of pertussis--2007 and beyond.
N Engl J Med. 2007 Jan 11;356(2):110-3. doi: 10.1056/NEJMp068288.
6
Pertussis--United States, 2001-2003.
MMWR Morb Mortal Wkly Rep. 2005 Dec 23;54(50):1283-6.
7
Pertussis vaccines for adolescents and adults.
Pediatrics. 2005 Sep;116(3):755-6. doi: 10.1542/peds.2005-0960.
9
Duration of immunity against pertussis after natural infection or vaccination.
Pediatr Infect Dis J. 2005 May;24(5 Suppl):S58-61. doi: 10.1097/01.inf.0000160914.59160.41.
10
The seroepidemiology of Bordetella pertussis infection in Western Europe.
Epidemiol Infect. 2005 Feb;133(1):159-71. doi: 10.1017/s0950268804003012.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验